Simona Rizzato

850 total citations · 1 hit paper
24 papers, 448 citations indexed

About

Simona Rizzato is a scholar working on Pulmonary and Respiratory Medicine, Genetics and Oncology. According to data from OpenAlex, Simona Rizzato has authored 24 papers receiving a total of 448 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Pulmonary and Respiratory Medicine, 14 papers in Genetics and 10 papers in Oncology. Recurrent topics in Simona Rizzato's work include Glioma Diagnosis and Treatment (14 papers), Brain Metastases and Treatment (7 papers) and Lung Cancer Diagnosis and Treatment (7 papers). Simona Rizzato is often cited by papers focused on Glioma Diagnosis and Treatment (14 papers), Brain Metastases and Treatment (7 papers) and Lung Cancer Diagnosis and Treatment (7 papers). Simona Rizzato collaborates with scholars based in Italy, United Kingdom and Netherlands. Simona Rizzato's co-authors include Roberta Rudà, Giuseppe Lombardi, Vittorina Zagonel, Marica Eoli, Ivan Lolli, Alba A. Brandes, Gian Luca De Salvo, Bruno Daniele, Francesco Pasqualetti and Stefano Indraccolo and has published in prestigious journals such as Journal of Clinical Oncology, The Lancet Oncology and Clinical Cancer Research.

In The Last Decade

Simona Rizzato

22 papers receiving 445 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial

2018 257 citations Giuseppe Lombardi, Gian Luca De Salvo et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Simona Rizzato Italy	10	300	148	139	133	128	24	448
Benedikte Hasselbalch Denmark	9	399 1.3×	136 0.9×	90 0.6×	151 1.1×	156 1.2×	22	491
Jeffrey Raizer United States	8	220 0.7×	158 1.1×	128 0.9×	75 0.6×	114 0.9×	12	390
Sarah Gaffey United States	9	243 0.8×	79 0.5×	148 1.1×	87 0.7×	152 1.2×	22	402
Joerg Felsberg Germany	12	247 0.8×	80 0.5×	75 0.5×	166 1.2×	227 1.8×	22	441
H. A. Fine United States	5	421 1.4×	144 1.0×	145 1.0×	174 1.3×	236 1.8×	6	580
Macarena I. de la Fuente United States	13	300 1.0×	79 0.5×	122 0.9×	106 0.8×	153 1.2×	36	510
Alberto Pïcca France	9	189 0.6×	92 0.6×	100 0.7×	81 0.6×	123 1.0×	27	339
Daniel Xia United States	10	203 0.7×	70 0.5×	72 0.5×	112 0.8×	264 2.1×	29	529
Santino Minichillo Italy	9	110 0.4×	120 0.8×	160 1.2×	137 1.0×	84 0.7×	17	347
Lisa Roberts-Rapp United States	12	248 0.8×	90 0.6×	272 2.0×	90 0.7×	282 2.2×	36	634

Countries citing papers authored by Simona Rizzato

Since Specialization

Citations

This map shows the geographic impact of Simona Rizzato's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Simona Rizzato with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Simona Rizzato more than expected).

Fields of papers citing papers by Simona Rizzato

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Simona Rizzato. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Simona Rizzato. The network helps show where Simona Rizzato may publish in the future.

Co-authorship network of co-authors of Simona Rizzato

This figure shows the co-authorship network connecting the top 25 collaborators of Simona Rizzato. A scholar is included among the top collaborators of Simona Rizzato based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Simona Rizzato. Simona Rizzato is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Costa, José Luís, et al.. (2025). Oligometastatic NSCLC: Current Perspectives and Future Challenges. Current Oncology. 32(2). 75–75. 2 indexed citations

Costa, José Luís, Alexandro Membrino, Simona Rizzato, et al.. (2024). The Role of ctDNA in the Management of Non-Small-Cell Lung Cancer in the AI and NGS Era. International Journal of Molecular Sciences. 25(24). 13669–13669. 4 indexed citations

Villani, Veronica, Elena Anghileri, Luca Prosperini, et al.. (2021). Adjuvant chemotherapy after severe myelotoxicity during chemoradiation phase in malignant gliomas. Is it feasibile? Results from AINO study (Italian Association for Neuro-Oncology). Journal of Neurology. 268(8). 2866–2875. 2 indexed citations

Lombardi, Giuseppe, Paola Del Bianco, Alba A. Brandes, et al.. (2021). Patient-reported outcomes in a phase II randomised study of regorafenib compared with lomustine in patients with relapsed glioblastoma (the REGOMA trial). European Journal of Cancer. 155. 179–190. 16 indexed citations

Padovan, Marta, Marica Eoli, Alessia Pellerino, et al.. (2021). Depatuxizumab Mafodotin (Depatux-M) Plus Temozolomide in Recurrent Glioblastoma Patients: Real-World Experience from a Multicenter Study of Italian Association of Neuro-Oncology (AINO). Cancers. 13(11). 2773–2773. 21 indexed citations

Corvaja, Carla, Giada Targato, Silvio Ken Garattini, et al.. (2021). The impact of COVID-19 pandemic on oncology workload: The experience of an Italian Reference Cancer Center.. Journal of Clinical Oncology. 39(15_suppl). e13520–e13520. 1 indexed citations

Indraccolo, Stefano, Gian Luca De Salvo, Mario Caccese, et al.. (2020). Phosphorylated Acetyl-CoA Carboxylase Is Associated with Clinical Benefit with Regorafenib in Relapsed Glioblastoma: REGOMA Trial Biomarker Analysis. Clinical Cancer Research. 26(17). 4478–4484. 28 indexed citations

Marinis, Filippo de, К. К. Лактионов, Artem Poltoratskiy, et al.. (2020). Afatinib in EGFR TKI-naïve patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer: Interim analysis of a Phase 3b study. Lung Cancer. 152. 127–134. 20 indexed citations

Pelizzari, Giacomo, Francesco Cortiula, Michele Bartoletti, et al.. (2020). Platinum-Based Chemotherapy in Older Patients with Non-Small Cell Lung Cancer: What to Expect in the Real World. Drugs & Aging. 37(9). 677–689. 2 indexed citations

10.

Lombardi, Giuseppe, Matteo Simonelli, Luisa Bellu, et al.. (2020). Defining the prognostic role of MGMT methylation value by pyrosequencing assay in glioblastoma patients: A large Italian multicenter study.. Journal of Clinical Oncology. 38(15_suppl). 2539–2539. 1 indexed citations

11.

Caccese, Mario, Marta Padovan, Marica Eoli, et al.. (2020). Depatuxizumab mafodotin (Depatux-M) plus temozolomide (TMZ) in recurrent glioblastoma patients: Real-world experience from a multicenter study of Italian Association of Neuro-Oncology (AINO).. Journal of Clinical Oncology. 38(15_suppl). 2544–2544. 2 indexed citations

12.

Lombardi, Giuseppe, Gian Luca De Salvo, Alba A. Brandes, et al.. (2018). Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial. The Lancet Oncology. 20(1). 110–119. 257 indexed citations breakdown →

13.

Carlo, Elisa De, Lorenzo Gerratana, Giovanna De Maglio, et al.. (2018). Defining a prognostic score based on O6-methylguanine-DNA methyltransferase cut-off methylation level determined by pyrosequencing in patients with glioblastoma multiforme. Journal of Neuro-Oncology. 140(3). 559–568. 9 indexed citations

14.

Ius, Tamara, Daniela Cesselli, Miriam Isola, et al.. (2018). Combining Clinical and Molecular Data to Predict the Benefits of Carmustine Wafers in Newly Diagnosed High-Grade Gliomas. Current Treatment Options in Neurology. 20(2). 3–3. 14 indexed citations

15.

Lombardi, Giuseppe, Gian Luca De Salvo, Roberta Rudà, et al.. (2018). Updated results of REGOMA: A randomized, multicenter, controlled open-label phase II clinical trial evaluating regorafenib in relapsed glioblastoma (GBM) patients (PTS).. Journal of Clinical Oncology. 36(15_suppl). 2047–2047. 2 indexed citations

16.

Lombardi, Giuseppe, Luisa Bellu, Veronica Villani, et al.. (2018). A large, multicenter, retrospective study to identify a cutoff of MGMT methylation status by quantitative pyrosequencing approach in patients (PTS) with glioblastoma (GBM).. Journal of Clinical Oncology. 36(15_suppl). 2012–2012. 1 indexed citations

17.

Fasola, Gianpiero, Ornella Belvedere, Fabio Barbone, et al.. (2017). P1.03-035 Does Screening with Low-Dose Computed Tomography (LDCT) of Asbestos Exposed Subjects Reduce Mortality for Lung Cancer (LC)?. Journal of Thoracic Oncology. 12(1). S563–S564. 1 indexed citations

18.

Fasola, Gianpiero, et al.. (2012). Adopting Integrated Care Pathways in Non–Small-Cell Lung Cancer: From Theory to Practice. Journal of Thoracic Oncology. 7(8). 1283–1290. 16 indexed citations

19.

Grossi, Francesco, Gianpiero Fasola, C. Rossetto, et al.. (2006). Phase II study of irinotecan and docetaxel in patients with previously treated non-small cell lung cancer: An Alpe-Adria Thoracic Oncology Multidisciplinary group study (ATOM 007). Lung Cancer. 52(1). 89–92. 9 indexed citations

20.

Grossi, Francesco, Ornella Belvedere, Gianpiero Fasola, et al.. (2004). Sequential chemotherapy with paclitaxel plus cisplatin, followed by vinorelbine, followed by gemcitabine in advanced non-small cell lung cancer: an Alpe-Adria Thoracic Oncology Multidisciplinary group study (ATOM 001). Lung Cancer. 46(1). 99–106. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact